Anxiety Disorders and Substance Use

What clients call 'just nerves' or 'needing something to take the edge off' is usually a specific, named DSM-5 anxiety disorder that responds to evidence-based treatment. When substance use is layered on top, the two conditions reinforce each other along a measurable neurobiological pathway. This article walks through the six DSM-5 anxiety disorders, the self-medication cycle that connects them to addiction, why the cycle worsens both conditions over time, and what integrated outpatient care looks like at The Archangel Centers in Tinton Falls, New Jersey, and Charlotte, North Carolina.

How common anxiety is

Anxiety disorders are the most prevalent mental health conditions in the United States. The National Institute of Mental Health estimates that roughly 19 percent of U.S. adults experience an anxiety disorder in any given year, and about 31 percent will meet diagnostic criteria for one at some point in their lives [1]. That is more than depression, more than substance use disorders considered alone, and more than any single category of mental illness.

Among adults in addiction treatment, the rate climbs sharply. SAMHSA reports that adults with a substance use disorder are roughly twice as likely as the general population to have a co-occurring anxiety or mood disorder, and the relationship runs in both directions: anxiety raises the risk of developing a substance use disorder, and substance use raises the risk of developing or worsening anxiety [3]. In NIDA's comorbidity work, the overlap is described as one of the most robust findings in the field, observable across age groups, substances, and care settings [4].

Anxiety is not a single condition. The DSM-5 names six adult anxiety disorders, each with its own clinical picture and each interacting with substance use differently [2]. Knowing which one is in play changes the treatment plan.

The self-medication pathway

The self-medication hypothesis, first formalized by Khantzian in 1985 and now backed by decades of neuroimaging and treatment-outcome data, says that people with anxiety often discover that certain substances reliably dampen anxiety symptoms, and that the discovery becomes the engine of a substance use disorder [3]. The biology behind it is concrete.

Alcohol is the most common. Within fifteen to twenty minutes of a first drink, alcohol enhances GABA inhibition (the brain's calming signal) and reduces glutamate excitation (the brain's activating signal). The result is a measurable, predictable softening of anxiety symptoms. Benzodiazepines like Xanax, Klonopin, Ativan, and Valium act on the same GABA system more directly, which is why they were prescribed for anxiety in the first place and why they carry dependence risk in long-term use [8]. Opioids quiet anxiety as part of their broader sedative effect through mu-opioid receptors that overlap with stress-response circuitry. Cannabis is bidirectional: at low doses and in certain individuals it calms, and at higher doses or in others it triggers panic.

The pattern is the same across substances. The first uses work. The substance does within minutes what no amount of trying-not-to-be-anxious had done before. The brain, which is fundamentally a pattern-learning organ, encodes the association: this substance, in this context, equals relief. Over weeks and months that learned association becomes the dominant anxiety-management strategy, and over months and years it becomes the only one [4].

Why the cycle gets worse

Chronic substance use does not just fail to fix anxiety. It actively worsens it through three mechanisms that compound over time [4].

• Rebound anxiety. When the substance wears off, the nervous system overshoots in the opposite direction. The post-drinking morning is more anxious than baseline. The afternoon after a short-acting benzodiazepine is more anxious than the morning. Each cycle resets the baseline a little higher than the day before.
• Withdrawal anxiety. As physical dependence develops, the nervous system requires the substance to feel normal. Periods without it produce acute anxiety symptoms that are often more severe than the original condition. For benzodiazepines and alcohol, untreated withdrawal also carries seizure risk, which is one of the reasons supervised taper matters [8].
• Neuroadaptation. The brain compensates for chronic substance exposure by changing receptor density and neurotransmitter levels. The GABA system that produces calm becomes less responsive. The glutamate system that produces arousal becomes more reactive. Imaging in chronic alcohol and benzodiazepine users shows measurable downregulation of GABA-A receptors and upregulation of stress circuitry [4]. Over time, the brain becomes more anxiety-prone, not less.

Why time alone does not fix it

Patients sometimes ask whether sustained sobriety, by itself, will resolve the anxiety. Often the answer is partial. The acute rebound resolves in days to weeks. The withdrawal-driven anxiety resolves over weeks to months as receptor populations recover. The underlying anxiety disorder, the condition that was there before the first drink, usually does not resolve on its own. That is what integrated treatment is for.

Why integrated treatment works

SAMHSA's clinical guidance for co-occurring disorders is unambiguous: integrated treatment that addresses both conditions in the same setting, by the same team, at the same time, produces better outcomes than sequential or parallel treatment [3]. Treating substance use without treating anxiety leaves the original driver intact, and the recovery is fragile. Treating anxiety without treating substance use leaves the brain still being reset by the substance, and the anxiety treatment underperforms.

In our outpatient programs at Tinton Falls and Charlotte, integrated care looks like a single intake assessment that screens for anxiety alongside substance use (GAD-7 for generalized anxiety, PHQ-9 for co-occurring depression, plus full biopsychosocial and ASAM or LOCUS criteria), a single treatment plan that addresses both presentations, group programming that includes evidence-based anxiety-management curriculum, individual therapy with one clinician who holds both conditions, and medication management when clinically indicated by a prescriber who understands the substance use context.

On medication, the working clinical principle is straightforward. Benzodiazepines are not the first choice for anxiety in patients with a substance use history. Selective serotonin reuptake inhibitors (SSRIs) are the evidence-based first-line treatment for generalized anxiety, panic, and social anxiety, and they are non-addictive [8]. Buspirone, certain anticonvulsants, and behavioral interventions fill in around them. The decision for any individual patient is made by the prescribing clinician after a full assessment.

What outpatient anxiety and addiction treatment includes

The integrated approach at the Partial Care and Intensive Outpatient level includes the components below. The specific mix and intensity are matched to severity at intake and adjusted as the client progresses through the continuum.

• Comprehensive intake. GAD-7 anxiety screening, PHQ-9 depression screening, Columbia suicide screening, biopsychosocial, ASAM (substance use) and LOCUS (mental health) assessments, medical and family history.
• **Cognitive-behavioral therapy for anxiety.** The most studied and most effective psychological treatment for generalized anxiety, panic, social anxiety, and specific phobia. Delivered in group and individual formats across the program.
• Stress regulation and skills. Diaphragmatic breathing, grounding, exposure-based skill building, behavioral activation, mindfulness practice. In NJ, the wellness room (anti-gravity massage chairs, yoga, breathwork) supports the work in a non-billable, supplemental capacity.
• Sleep restoration. Sleep is destroyed by both anxiety and substance use, and rebuilding it is a clinical priority. Sleep hygiene, evening routine work, and medication review where appropriate.
• Psychiatric medication management. SSRI initiation or optimization, buspirone or anticonvulsant adjuncts where indicated, and benzodiazepine taper when an existing prescription is in place. Managed by clinicians experienced in co-occurring care.
• Family programming and case management. Anxiety often patterns into family relationships, and family therapy changes the system that maintains it. Case management covers FMLA, short-term disability, employment coordination, and legal coordination with releases.

How the schedule supports anxiety recovery

Anxiety recovery is partly about content (skills, insight, medication) and partly about structure. The NJ Partial Care schedule runs 9:00 AM to 3:15 PM Monday through Friday, with Saturday programming from 9:00 AM to 12:30 PM. Arrival and grounding run from 8:30 to 9:00 AM with coffee before the first group. That daytime structure of predictable groups, regular meals, and a consistent return home is itself anxiety-reducing for most clients. The nervous system rebuilds best inside a routine.

IOP runs three or five days per week at three clinical hours per session, for clients who can hold a more independent structure. OP is a lighter-touch step-down. Virtual Treatment provides the same clinical programming remotely for NJ residents who cannot attend in person.

On benzodiazepine taper

A meaningful share of clients arrive on an existing benzodiazepine prescription, often years old, sometimes from a primary care provider who started it during an acute episode and never had a clean point to stop. The ASAM and APA clinical guidance is consistent: long-term benzodiazepine use carries cognitive, fall, and dependence risks; abrupt discontinuation carries seizure risk; and the only safe path off is a slow, supervised taper inside an integrated care plan [8].

What that looks like clinically: the prescribing clinician confirms the current dose and history, screens for withdrawal-risk factors, and sets a taper rate that is usually measured in weeks to months rather than days. An SSRI or other non-addictive medication is often initiated first to give the underlying anxiety a stable floor before the benzodiazepine comes down. Symptoms are tracked through group and individual sessions, and the rate is adjusted to what the client can actually tolerate. The work is uncomfortable but predictable, and most clients move through it successfully when it is held inside a structured program.

If you are reading this and you have been told you 'have to' get off your benzodiazepine before any treatment program will accept you, that framing is outdated. Integrated outpatient programs taper as part of the treatment plan, not as a precondition for it.